ClinicalTrials.gg
CompletedNCT05865548Updated Aug 13, 2024

Addition of Aspirin to Standard of Care in Oral Cancer

A Phase 2/3 interventional study of Aspirin 150 mg and Standard of care in Oral Cancer, sponsored by Banaras Hindu University. Completed at 1 site in India. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by Banaras Hindu University · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Mouth Neoplasms with a site in India — 8 open to participants now, 9 under way, 1 of them phase 3. Mouth Neoplasms · India.

Enrollment
17th of 22
60 · median 140
Started
2023
the only one that year
Phase 2/3
2 of 23
none open now
Registered
16th of 23
by date
Lead sponsor
4 of 23
Banaras Hindu University

Among the 23 studies in Mouth Neoplasms with a site in India, this one is the 17th largest by enrollment of the 22 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 2/3, and was the 16th registered.

Mouth Neoplasms

447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.

Browse Mouth Neoplasms studies →

Open to participants now

8 of the 23 studies in Mouth Neoplasms with a site in India are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 97 Mouth Neoplasms studies recruiting now, 58 (60%) set no upper age limit and 23 (24%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Mouth Neoplasms with a site in India, or all of them as a file.
02

Study summary

Despite accumulating evidence of the benefit of aspirin in cancer, its effect on improving cancer survival is still debated since the mechanism by which it impacts cancer survival is not completely understood and the published data are discordant. There have been 4 randomized controlled trials (RCT) showing mixed results from no effect to improved survival. Several retrospective and observational studies have reported a survival advantage of adding aspirin to the treatment for various cancers. A meta-analysis of 118 studies, 63 of them specifically reporting on cancer mortality and the rest on all-cause mortality, found a 21% reduction in cancer deaths and about 20% reduction in all-cause mortality (pooled hazard ratio (HR): 0.79; 95% confidence intervals: 0.73, 0.84).

However, the evidence is still lacking and there is need to do more RCT

Read the detailed description

Aspirin (ASA), an NSAID, is a well-known antipyretic and analgesic agent and is used to prevent recurrent transient ischemic attacks or strokes. In addition to its classical anti- inflammatory function, clinical and epidemiological studies indicate that aspirin can be used as a preventive or therapeutic agent in multiple cancers, including oral cancers

While the exact mechanism through which NSAIDs contribute to chemo prevention is not completely understood, Aspirin inhibits the enzyme Cox; Cox-1 and Cox-2 are well characterized. Cox converts a arachidonic acid to prostaglandin H2, which in turn produces biologically active prostaglandins that influence path physiological processes in a range of tissues including angiogenesis, apoptosis, cell proliferation and migration, inflammatory response and thrombosis. Inhibition of prostaglandin synthesis is considered the pre dominant mechanism by which NSAIDs act as anti-inflammatory agents, but it is unclear whether the anti-cancer properties of these agents can be solely attributed to Cox inhibition.

Recently, Cox-2 over expression has been identified in a number of different malignancies and it has been hypothesized that Cox-2 prostaglandins promote tumor genesis by inhibiting apoptosis, modulating the immune system and regulating tumor associated angiogenesis.

A detailed search of literature and bio informatics analysis of the data obtained showed that the effect of Aspirin on survival and prevention of recurrence and secondary cancer could be due to its effect on following 11 genes PTGS2, PIK3CA, PARP1, PARP2, VEGFA, KDR, PTGES2, NFKB1, P53, FLT1, VEGFR. These genes not only interact and control each other but also control cell cycle regulation through other genes as shown below. These could be due to co expression, physical interactions, shared domains or predicted interactions in absence of data.

Based on the gene-gene and protein-protein interactions they can be clustered into three with PTGES2, PTGS2 and p53 being in first cluster (figure 2 below), the NGS data obtained from the previous patients also showed the p53 to be the primary driver gene (unpublished data, submitted) in nearly 50% of the subjects. It has also been shown that patients with p53 mutations

have poor survival and increased recurrence rates compared to those without p53 mutations. This coupled with literature showing improved survival and low recurrence in patients receiving Aspirin suggest the need for a RCT as this has never been done before.

03

Conditions studied

  • Oral Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All proven cases of primary oral cancers.
  • Stage T1 to T4, N0 to N3, M0 to M1.
  • Age above 18.
  • ' performance status more than 70, 0 to 2
  • >8.0 gm/dL
  • Total count >4000 cu mm
  • count >100000 Serum creatinine \<1.0mg
  • Liver enzymes up to 1.5 times normal
  • \<1.0mg

Exclusion criteria

Exclusion Criteria:

  • Patients with acid peptic disease
  • Pregnant and lactating women.
  • Patients not willing to participate.
  • Patients with known allergy to NSAID
  • Patients with Asthma, rhinitis and nasal polyps
  • Presence of viral fever
  • Use of any other blood thinner like warfarin, heparin or low molecular weight heparin
  • bleeding/blood-clotting disorders (such as hemophilia, vitamin K deficiency, low count)
  • pyruvate kinase or G6PD deficiency
  • Patients receiving mifepristone, acetazolamide, , dichlorphenamide, methotrexate, valproic acid, herbal medications (such as ginkgo biloba)
  • Patients with recent history of anti-viral vaccines
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Interventional arm

    Aspirin 150mg PO daily along with standard of care

    Drug: Aspirin 150 mg

  • Active comparator
    Standard of care

    Standard of care as per the stage of disease and guidelines i.e. Surgery, Surgery with radiation or palliative chemotherapy as per investigators choice

    Procedure: Standard of care

Interventions

  • DrugAspirinStudies of AspirinAspirin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Aspirin 150 mg PO daily

  • ProcedureStandard of care

    Surgery with or without radiation, palliative chemo as per investigators choice

    Also known as: Radiation, chemotherapy

06

What researchers measure

Primary outcomes

  1. Adverse events

    Number of participants with treatment-related adverse events as assessed by WHO toxicity criteria

    Time frame: 4 weeks

Secondary outcomes

  1. Disease free survival

    Local recurrence or metastasis from the time from the diagnosis to the closer of study

    Time frame: through study completion, an average of 2 year

  2. Overall survival

    Death from the time of diagnosis to closer of study

    Time frame: through study completion, an average of 2 year

07

Study locations

1 site
  • Banaras Hindu University
    Varanasi, UP 221005, India
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2023 to primary completion in Aug 2024, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
May 19, 2023
StartActual
May 17, 2023
Primary completionActual
Aug 10, 2024
CompletionActual
Aug 10, 2024
Last update
Aug 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05865548
Lead sponsor
Banaras Hindu University
Responsible party
Manoj Pandey (Professor, Banaras Hindu University) — Principal investigator
First posted
May 19, 2023
Start date
May 17, 2023
Primary completion
Aug 10, 2024
Completion
Aug 10, 2024
Last update
Aug 13, 2024

Study contacts

Manoj Pandey
principal investigator · Professor

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion